恩杂鲁胺-话题@MedSci

vue-cli-subapp

#恩杂鲁胺#

2篇内容 | 2870人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2259667, encodeId=6293225966eea, content=<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a> <a href='/topic/show?id=641e1139ea8' target=_blank style='color:#2F92EE;'>#mCRPC#</a> <a href='/topic/show?id=68f8125869b7' target=_blank style='color:#2F92EE;'>#他拉唑帕尼#</a>, objectTitle=Lancet Oncol | TALAPRO-2试验结果：他拉唑帕尼联合恩杂鲁胺在转移性去势抵抗性前列腺癌患者中的生活质量改善, objectType=article, longId=870966, objectId=e3328e096605, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240801/1722478199513_92910.jpg, objectUrl=/article/show_article.do?id=e3328e096605, replyNumber=0, likeNumber=12, createdTime=2025-04-08, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=e3328e096605, moduleTitle=Lancet Oncol | TALAPRO-2试验结果：他拉唑帕尼联合恩杂鲁胺在转移性去势抵抗性前列腺癌患者中的生活质量改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e3328e096605)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2234309, encodeId=21bb2234309e4, content=<a href='/topic/show?id=b6f29563625' target=_blank style='color:#2F92EE;'>#醋酸阿比特龙#</a> <a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a> <a href='/topic/show?id=a17393408d0' target=_blank style='color:#2F92EE;'>#转移性去势抵抗性前列腺癌#</a>, objectTitle=World J Urol：恩杂鲁胺与醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者新发或恶化的2型糖尿病情况比较, objectType=article, longId=849262, objectId=870f84926281, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240801/1722479677148_92910.jpg, objectUrl=/article/show_article.do?id=870f84926281, replyNumber=0, likeNumber=49, createdTime=2024-10-31, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=870f84926281, moduleTitle=World J Urol：恩杂鲁胺与醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者新发或恶化的2型糖尿病情况比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=870f84926281)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2192947, encodeId=6f57219294ee8, content=<a href='/topic/show?id=2cfa10e777e8' target=_blank style='color:#2F92EE;'>#他拉唑帕利#</a> <a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a> <a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>, objectTitle=JCO：FDA批准他拉唑帕利联合恩杂鲁胺用于治疗HRR基因突变的晚期去势抵抗性前列腺癌, objectType=article, longId=816994, objectId=8b96816994b0, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240313/1710306304033_6145188.jpg, objectUrl=/article/show_article.do?id=8b96816994b0, replyNumber=0, likeNumber=90, createdTime=2024-03-13, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8b96816994b0, moduleTitle=JCO：FDA批准他拉唑帕利联合恩杂鲁胺用于治疗HRR基因突变的晚期去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8b96816994b0)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2169307, encodeId=53b9216930e35, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a> <a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a> <a href='/topic/show?id=60cb10e52478' target=_blank style='color:#2F92EE;'>#CRISPR - Cas9#</a>, objectTitle=Cancer Res：中山大学李永红/周芳坚/王军发现前列腺癌恩杂鲁胺耐药的潜在机理, objectType=article, longId=801252, objectId=e7ab801252dd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/close-up-of-doctors-with-clipboard-at-hospital-PXE5DKE.jpg, objectUrl=/article/show_article.do?id=e7ab801252dd, replyNumber=0, likeNumber=100, createdTime=2023-11-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=e7ab801252dd, moduleTitle=Cancer Res：中山大学李永红/周芳坚/王军发现前列腺癌恩杂鲁胺耐药的潜在机理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e7ab801252dd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=886182, encodeId=6d19886182c9, content=与<a href='/topic/show?id=de489e856c6' target=_blank style='color:#2F92EE;'>#阿比特龙#</a>或<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a>等雄激素信号抑制剂相比，<a href='/topic/show?id=02553650509' target=_blank style='color:#2F92EE;'>#卡巴他赛#</a>可显著改善转移性去势耐药性<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>患者的临床结果。卡巴他赛是第二代<a href='/topic/show?id=49ad10392134' target=_blank style='color:#2F92EE;'>#紫杉*类#</a>药物, objectTitle=NEJM：卡巴他赛用于治疗耐药性前列腺癌, objectType=article, longId=185296, objectId=6e62185296b2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/webeditor/uploadfile/201912/20191226184419664.jpg, objectUrl=/article/show_article.do?id=6e62185296b2, replyNumber=0, likeNumber=306, createdTime=2020-09-17, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6e62185296b2, moduleTitle=NEJM：卡巴他赛用于治疗耐药性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6e62185296b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=601379, encodeId=242c6013e972, content=<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a>延长去势耐受前列腺癌生存11个月，还是相当不错吧, objectTitle=NEJM：恩杂鲁胺用于治疗去势耐受性前列腺癌, objectType=article, longId=195323, objectId=989d195323d7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202064/1591266757240_2051781.jpg, objectUrl=/article/show_article.do?id=989d195323d7, replyNumber=0, likeNumber=181, createdTime=2020-06-04, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=989d195323d7, moduleTitle=NEJM：恩杂鲁胺用于治疗去势耐受性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=989d195323d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

恩杂鲁胺

2020-05-29

梅斯管理员

#恩杂鲁胺# #mCRPC# #他拉唑帕尼#

Lancet Oncol | TALAPRO-2试验结果：他拉唑帕尼联合恩杂鲁胺在转移性去势抵抗性前列腺癌患者中的生活质量改善

2025-04-08发表于陕西省

梅斯管理员

#醋酸阿比特龙# #恩杂鲁胺# #转移性去势抵抗性前列腺癌#

World J Urol：恩杂鲁胺与醋酸阿比特龙治疗转移性去势抵抗性前列腺癌患者新发或恶化的2型糖尿病情况比较

2024-10-31发表于上海

梅斯管理员

#他拉唑帕利# #恩杂鲁胺# #前列腺癌#

JCO：FDA批准他拉唑帕利联合恩杂鲁胺用于治疗HRR基因突变的晚期去势抵抗性前列腺癌

2024-03-13发表于上海

梅斯管理员

#前列腺癌# #恩杂鲁胺# #CRISPR - Cas9#

Cancer Res：中山大学李永红/周芳坚/王军发现前列腺癌恩杂鲁胺耐药的潜在机理

2023-11-18发表于上海

lovetcm

与#阿比特龙#或#恩杂鲁胺#等雄激素信号抑制剂相比，#卡巴他赛#可显著改善转移性去势耐药性#前列腺癌#患者的临床结果。卡巴他赛是第二代#紫杉*类#药物

NEJM：卡巴他赛用于治疗耐药性前列腺癌

2020-09-17

lovetcm

#恩杂鲁胺#延长去势耐受前列腺癌生存11个月，还是相当不错吧

NEJM：恩杂鲁胺用于治疗去势耐受性前列腺癌

2020-06-04